These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 11075012)

  • 1. The nitric oxide connection: hyperbaric oxygen therapy, becaplermin, and diabetic ulcer management.
    Boykin JV
    Adv Skin Wound Care; 2000; 13(4 Pt 1):169-74. PubMed ID: 11075012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of becaplermin for nonhealing neuropathic diabetic foot ulcers.
    Sibbald RG; Torrance G; Hux M; Attard C; Milkovich N
    Ostomy Wound Manage; 2003 Nov; 49(11):76-84. PubMed ID: 14652415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New developments in the treatment of diabetic foot ulcers].
    Bakker K; Schaper NC
    Ned Tijdschr Geneeskd; 2000 Feb; 144(9):409-12. PubMed ID: 10719543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study.
    Wieman TJ; Smiell JM; Su Y
    Diabetes Care; 1998 May; 21(5):822-7. PubMed ID: 9589248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost-effectiveness of treating diabetic lower extremity ulcers with becaplermin (Regranex): a core model with an application using Swedish cost data.
    Persson U; Willis M; Odegaard K; Apelqvist J
    Value Health; 2000; 3 Suppl 1():39-46. PubMed ID: 16464208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of chronic wound fluid on the structure and biological activity of becaplermin (rhPDGF-BB) and becaplermin gel.
    Castronuovo JJ; Ghobrial I; Giusti AM; Rudolph S; Smiell JM
    Am J Surg; 1998 Aug; 176(2A Suppl):61S-67S. PubMed ID: 9777974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of Becaplermin in the treatment of diabetic foot ulcers in four European countries.
    Ghatnekar O; Persson U; Willis M; Odegaard K
    Pharmacoeconomics; 2001; 19(7):767-78. PubMed ID: 11548912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant human platelet-derived growth factor-BB (becaplermin) for healing chronic lower extremity diabetic ulcers: an open-label clinical evaluation of efficacy.
    Embil JM; Papp K; Sibbald G; Tousignant J; Smiell JM; Wong B; Lau CY
    Wound Repair Regen; 2000; 8(3):162-8. PubMed ID: 10886806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of topical recombinant human platelet-derived growth factor-BB (becaplermin) in healing of chronic mixed arteriovenous lower extremity diabetic ulcers.
    Miller MS
    J Foot Ankle Surg; 1999; 38(3):227-31. PubMed ID: 10384364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Becaplermin: recombinant platelet derived growth factor, a new treatment for healing diabetic foot ulcers.
    Nagai MK; Embil JM
    Expert Opin Biol Ther; 2002 Feb; 2(2):211-8. PubMed ID: 11849120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effective management of recalcitrant diabetic foot ulcers.
    Albert S
    Clin Podiatr Med Surg; 2002 Oct; 19(4):483-91. PubMed ID: 12471856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of Regranex gel for diabetic foot ulcers.
    Piascik P
    J Am Pharm Assoc (Wash); 1998; 38(5):628-30. PubMed ID: 9782698
    [No Abstract]   [Full Text] [Related]  

  • 13. Tissue-specific role of Nrf2 in the treatment of diabetic foot ulcers during hyperbaric oxygen therapy.
    Dhamodharan U; Karan A; Sireesh D; Vaishnavi A; Somasundar A; Rajesh K; Ramkumar KM
    Free Radic Biol Med; 2019 Jul; 138():53-62. PubMed ID: 31035003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Becaplermin gel in the treatment of pressure ulcers: a phase II randomized, double-blind, placebo-controlled study.
    Rees RS; Robson MC; Smiell JM; Perry BH
    Wound Repair Regen; 1999; 7(3):141-7. PubMed ID: 10417749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies.
    Smiell JM; Wieman TJ; Steed DL; Perry BH; Sampson AR; Schwab BH
    Wound Repair Regen; 1999; 7(5):335-46. PubMed ID: 10564562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperbaric oxygen, oxidative stress, NO bioavailability and ulcer oxygenation in diabetic patients.
    Efrati S; Gall N; Bergan J; Fishlev G; Bass A; Berman S; Hamad-Abu R; Feigenzon M; Weissgarten J
    Undersea Hyperb Med; 2009; 36(1):1-12. PubMed ID: 19341122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Mechanism of Hyperbaric Oxygen Therapy in the Treatment of Chronic Wounds and Diabetic Foot Ulcers.
    Johnston BR; Ha AY; Brea B; Liu PY
    R I Med J (2013); 2016 Feb; 99(2):26-9. PubMed ID: 26827082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of hyperbaric oxygen and growth factors on rabbit ear ischemic ulcers.
    Zhao LL; Davidson JD; Wee SC; Roth SI; Mustoe TA
    Arch Surg; 1994 Oct; 129(10):1043-9. PubMed ID: 7944933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wound nitric oxide bioactivity: a promising diagnostic indicator for diabetic foot ulcer management.
    Boykin JV
    J Wound Ostomy Continence Nurs; 2010; 37(1):25-32; quiz 33-4. PubMed ID: 20075688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant Hyperbaric Oxygen Therapy Enhances Healing of Nonischemic Diabetic Foot Ulcers Compared With Standard Wound Care Alone.
    Salama SE; Eldeeb AE; Elbarbary AH; Abdelghany SE
    Int J Low Extrem Wounds; 2019 Mar; 18(1):75-80. PubMed ID: 30836807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.